Editorial Staff

Study: Growth of Antibiotic-Resistant Infections Could Have Massive Human, Financial Costs

/in , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Dysfunctional market, perverse incentives caused by Medicare reimbursement rates contribute to problem

BOSTON – The world was blindsided by COVID-19, but a new Pioneer Institute study finds that even as we continue to wrestle with the pandemic, another threat looms that scientists have long known about but the nation has thus far failed to address: the growth of antibiotic-resistant infections.

“Market dysfunction and perverse Medicare reimbursement rates have led to a growth in infections that resist antibiotics,” said Gunnar Esiason, author of “Antimicrobial Resistance: Learning from the current global health crisis to prevent another one.”  If we don’t solve this problem, the human and economic costs are likely to be astronomical.”

In the U.S., around two million people per year contract infections that are resistant to antibiotics and as many as 23,000 of them die.  These drug-resistant infections account for $20 billion in health care costs.

If unchecked, it’s forecast that the problem could claim 10 million lives per year worldwide and be responsible for the loss of $100 trillion in economic output by 2050.

Antibiotic resistance is driven by years of overuse and misuse of antibiotics.  Medicare is the nation’s largest payer, and its recipients account for the majority of resistant infections.  Because hospitals receive the same reimbursement whether they use an older generic drug or a new drug that is likely to be more expensive, there is a financial incentive to prescribe the older drugs, even if those drugs may not be as effective because patients have built up resistance to them.

The continuing use of older drugs exacerbates the antibiotic resistance problem.  It can also result in higher health care costs because additional treatments are required to treat the infection, or cause hospitals to use unnecessarily strong antibiotics to treat it effectively.

Hospitals favoring older generic drugs even if they are less effective makes it harder for new drugs to recoup development costs, which can be up to $2.6 billion.  As a result, investment is down and the number of new antibiotics approved by the FDA has fallen in recent years.  In addition, companies working on new antibiotics are more likely to be small firms or start-ups that are less financially stable.

With its large concentration of life science companies, Massachusetts could be particularly hard hit if investment in new antibiotics continues to lag.

One effort to address the antibiotic-resistant infection problem is the DISARM Act, which was introduced in Congress last year.  The legislation would increase Medicare antibiotic reimbursements and eliminate the incentive to prescribe less expensive drugs that are often less effective by allowing for the reimbursement of all antibiotics, regardless of cost.  Backers argue that the bill would slow the growth of resistant infections by ending the overuse of older drugs that have become less effective, and that newer, more effective antibiotics could reduce long-term costs.

Esiason also recommends mounting a broad awareness campaign that would tie this impending public health and economic threat to our current battle against COVID-19.

About the Author

Gunnar Esiason is a cystic fibrosis and rare disease patient leader, who is passionate about early stage drug development, patient empowerment and health policy. He is a second-year M.B.A. student at the Tuck School of Business at Dartmouth and is also working towards a Master of Public Health degree at the Dartmouth Institute for Health Policy and Clinical Practice. At Tuck, Gunnar serves as a Tuck Center for Health Care MBA Fellow, a health care club co-chair and a club hockey captain. Prior to Tuck, Gunnar received a BA form Boston College in 2013, worked on an enteral feeding product at a medical nutrition company, was appointed to the board of directors at the Boomer Esiason Foundation, and was the head coach of his high school alma mater’s varsity hockey team. Gunnar maintains the roles of patient advocate and director of patient outreach at the Boom­er Esiason Foundation.

He has consulted on clinical trial development, a real-world evidence population health study, and a cystic fibrosis-specific mental health and wellness screening tool. In 2019, Gunnar delivered the pre-commencement address at the St. Louis Uni­versity School of Medicine commencement exercises. He has also been featured as a keynote speaker at more than two-doz­en top medical centers, biotech conferences, and health indus­try events across the United States. His health policy opinions have been featured in Newsweek, The New York Daily News, The Hill, US News & World Report, and Morning Consult.

About Pioneer

Mission: Pioneer Institute develops and communicates dynamic ideas that advance prosperity and a vibrant civic life in Massachu­setts and beyond.

Vision: Success for Pioneer is when the citizens of our state and nation prosper and our society thrives because we enjoy world-class options in education, healthcare, transportation and economic opportunity, and when our government is limited, accountable and transparent.

Values: Pioneer believes that America is at its best when our citizenry is well-educated, committed to liberty, personal responsibili­ty, and free enterprise, and both willing and able to test their beliefs based on facts and the free exchange of ideas.

Get Updates On Our Life Sciences Work!

Related Posts

In The Era Of COVID-19, Mass. Needs To Get Long-Term Care Right

0 Comments
/
This op-ed originally appeared in WGBH News. In much of the…

Holyoke Soldiers’ Home Study Targets Inadequate Nursing Home Staffing Standards

Standards enforced at the federal and state levels are insufficient to address chronic staffing issues reported by staff and residents’ families at the Holyoke Soldiers’ Home, making that facility particularly vulnerable to the COVID-19 pandemic, according to new Pioneer Institute research.

Hubwonk Ep. 5: COVID Calling: How answering the tracing phone call will move us forward

0 Comments
/
In this episode, Host Joe Selvaggi and Co-Host Barbara Anthony speak with the heads of Partners in Health Drs. Sheila Davis & John Welch on how they are bringing their expertise battling Ebola in West Africa to defeating the COVID-19 epidemic in Massachusetts. They explore precisely how and why tracing is an essential element in battling the epidemic.

National Study Finds Most States Lack Healthcare Price Transparency Laws

At a time when the coronavirus pandemic has caused massive shifts in state policies on telehealth and scope of practice in healthcare, a new Pioneer Institute study underscores that most of the 50 states continue to suffer from weak laws regarding price transparency.  The study identified states that have laws that require carriers, providers or both to provide personalized cost information to consumers before obtaining healthcare services.  Fully 33 states placed in the lowest of the three broad analytic tiers on the strength of their state healthcare transparency laws. 

Conquering COVID-19: When and From Where Will Vaccines and Therapies Emerge?

0 Comments
/
This week on Hubwonk, Host Joe Selvaggi is joined by Pioneer’s Bill Smith, Visiting Fellow in Life Sciences, and Dr. Peter Kolchinsky, Harvard-trained virologist, biotech investor and author of the new book, The Great American Drug Deal, to learn how the SARS-CoV2 works, what a vaccine may look like, and how we might produce it to scale.

A Tipping Point for Telehealth – Bringing Healthcare into Your Home

0 Comments
/
This week on "Hubwonk," Joe Selvaggi and Josh Archambault talk with Dr. Roy Schoenberg, Chief Executive of Amwell, a global telehealth technology company headquartered in Boston, about the promise of telemedicine and how the COVID-19 pandemic has catalyzed broader adoption.

Buoy Health – Intelligent Front Door to Optimized Healthcare

0 Comments
/
In this first episode of Pioneer's new podcast, Hubwonk, host Joe Selvaggi and Pioneer Senior Fellow in Healthcare Josh Archambault talk with Dr. Andrew Le, cofounder and Chief Executive Officer of Buoy Health.

Elderly people were already vulnerable to COVID-19. Then it came to nursing homes.

0 Comments
/
Last week, reports of mismanagement and negligence regarding…

Transparency Needed at Long-term Care Facilities

0 Comments
/
The anxiety of having a parent in a nursing home under the constant…

COVID-19 Roundup from Pioneer: Will plans to re-open hurt civil liberties?; COVID-19 model skeptic; SCOTUS returns!; New podcast, HubWonk; 5 Tips for online learning & more!

0 Comments
/
Pioneer staff share their top picks for COVID-19 stories highlighting useful resources, best practices, and questions we should be asking our public and private sector leaders.

New Study Calls for Re-thinking Massachusetts’ COVID-19 Care Standards

Pioneer's new study raises concerns about the Massachusetts Department of Public Health’s (DPH’s) Crises Standards of Care (CSC) issued earlier this month, which bear the earmarks of a state bureaucratic effort and should be rethought under a process that includes a thorough vetting by Massachusetts citizens.

COVID-19 Roundup from Pioneer: Tracking drug discovery efforts; Secrets to Germany’s success; Unemployment tsunami; Voc-techs answering the call; COVID prevalence by town & more!

0 Comments
/
Pioneer staff share their top picks for COVID-19 stories highlighting useful resources, best practices, and questions we should be asking our public and private sector leaders.

COVID-19 Roundup from Pioneer: Antibodies & serology tests to the rescue; Why such wide-ranging forecasts?; the Droplets v. Aerosol debate; Crowdsourcing symptoms & more!

0 Comments
/
Pioneer staff share their top picks for COVID-19 stories highlighting useful resources, best practices, and questions we should be asking our public and private sector leaders.

New Report: Quality Adjusted Life Years (QALY) Methodology Discriminates Against Older Americans, Threatens to Deny Seniors Access to Life-Saving Care

New report asserts that with older americans more vulnerable during the COVID-19 pandemic, all health plans should avoid using the QALY methodology when assessing the value of care for older patients

Quality Adjusted Life Years (QALY): The Threat to Older Americans

0 Comments
/
This report examines how the QALY methodology to determine drug treatment value threatens to discriminate against older adults by placing a lower value on treatments that would extend the life of or improve quality of life for older patients.  This clear bias against providing access to therapies to seniors comes at a critical and especially vulnerable time for older Americans given the coronavirus disease (COVID-19). 

COVID-19 Roundup from Pioneer: When will COVID-19 peak in MA?; Life in the aftermath; Tracking potential treatments; Getting America working again; Taking virtual learning to new heights & more!

0 Comments
/
Pioneer staff (and readers) share their top picks for COVID-19 stories highlighting useful resources, best practices, and questions we should be asking our public and private sector leaders.

COVID-19 Roundup from Pioneer: When should America re-open?, $2T federal relief impact, Tax deadline pushed, COVID-19 video contest & more!

0 Comments
/
Pioneer staff share their top picks for COVID-19 stories highlighting useful resources, best practices, and questions we should be asking our public and private sector leaders.

COVID-19 Roundup from Pioneer: Why the divergent fatality rates?, Time for Telehealth, Missing the Greatest Generation, Senator profiting from COVID-19 & more!

0 Comments
/
Pioneer staff share their top picks for COVID-19 stories highlighting…